Chief Executive Officer, WellDoc
As CEO, Kevin has led the WellDoc® team in the successful launch and continued development of the first FDA-cleared mobile prescription therapy for adults with type 2 diabetes – BlueStar®. Kevin oversees all WellDoc business related to consumer and business enterprise strategy and is responsible for establishing new strategic alliances. Under his leadership, the WellDoc team has engineered an innovative commercial approach to position BlueStar in the marketplace, which has attracted key investors such as Johnson & Johnson, Samsung and Merck GHI, and has positioned WellDoc as a leader in the development of digital therapeutics.
Prior to joining WellDoc in 2014, Kevin had an extensive career in biotech and pharmaceuticals. Most recently, Kevin served as the Vice President of Sales and Marketing at Human Genome Sciences where he hired and led the commercial organization responsible for the successful launch of Benlysta®.
Kevin also served as the Vice President of Sales and Marketing of the Hematology Franchise at Genentech where he led the team through the strategic development, sales and marketing execution for Rituxan®. Prior to his tenure at Genentech, Kevin held numerous sales and marketing roles of increasing responsibility over 14 years at Abbott Laboratories where he worked on key product launches, including Depakote®, Biaxin®, Kaletra®, Micardis® and Tricor®.